MELT-300
Phase 2- Indications
- Anxiety, Pain
Company intelligence / Profile preview
Melt Pharmaceuticals
United Statesmeltpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Melt Pharmaceuticals recently reported positive topline efficacy results from a pivotal Phase 3 trial of its lead product candidate, MELT‑300, a non-IV, non-opioid sublingual tablet for procedural sedation in cataract surgery. The study met safety and efficacy endpoints under an FDA Special Protocol Assessment. The company plans to seek regulatory approval via the FDA’s 505(b)(2) pathway[6].
- Therapeutic areas
- OtherOphthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Catalent (for Zydis® delivery technology)
Beyond the preview
Go deeper on Melt Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melt Pharmaceuticals.